secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2021-11-08T23:59:59+00:00
Accession:  0001178913-21-003411
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab names Donald Marvin CFO, EVP & COO; outgoing interim CFO stays as advisor
--------------------------------------------------------------------------------

- Donald Marvin appointed CFO, EVP, and COO effective November 8, 2021.
- Sigal Fattal's engagement as interim CFO concluded; she will serve as senior consultant to Marvin.
- Marvin receives $460k base salary, 45% bonus potential, $25k signing bonus, and equity (1.5% + 0.5% performance) vesting over 4 years.
- Marvin has over 35 years experience; previous roles include EVP/CFO at Lodo Therapeutics, Chairman/CEO at Concentric, co-founder of Orchid BioSciences.
- CEO Dale Pfost cites Marvin's expertise in building life sciences companies through organic growth and strategic M&A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003411/0001178913-21-003411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003411/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-21-003411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer